MX2022014466A - Combinacion de acetil leucina y 4-aminopiridina o acetazolamida para tratar la ataxia. - Google Patents
Combinacion de acetil leucina y 4-aminopiridina o acetazolamida para tratar la ataxia.Info
- Publication number
- MX2022014466A MX2022014466A MX2022014466A MX2022014466A MX2022014466A MX 2022014466 A MX2022014466 A MX 2022014466A MX 2022014466 A MX2022014466 A MX 2022014466A MX 2022014466 A MX2022014466 A MX 2022014466A MX 2022014466 A MX2022014466 A MX 2022014466A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- acetazolamide
- aminopyridine
- leucine
- acetyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063028760P | 2020-05-22 | 2020-05-22 | |
| PCT/IB2021/054399 WO2021234642A1 (en) | 2020-05-22 | 2021-05-20 | The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014466A true MX2022014466A (es) | 2022-12-13 |
Family
ID=76181172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014466A MX2022014466A (es) | 2020-05-22 | 2021-05-20 | Combinacion de acetil leucina y 4-aminopiridina o acetazolamida para tratar la ataxia. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230201150A1 (https=) |
| EP (1) | EP4153161A1 (https=) |
| JP (1) | JP2023526517A (https=) |
| KR (1) | KR20230015433A (https=) |
| CA (1) | CA3179105A1 (https=) |
| MX (1) | MX2022014466A (https=) |
| WO (1) | WO2021234642A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886986A1 (en) * | 2018-12-06 | 2021-10-06 | IntraBio Ltd | Deuterated analogs of acetyl-leucine |
| WO2025264957A2 (en) * | 2024-06-20 | 2025-12-26 | Intrabio Inc. | Acetyl leucine for treating neurodevelopmental disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| JP2009269856A (ja) * | 2008-05-07 | 2009-11-19 | Nobufumi Ono | 異常行動防止薬及びこれを含むインフルエンザ治療薬 |
| LT2588130T (lt) | 2010-06-25 | 2016-12-12 | Shire Human Genetic Therapies, Inc. | Terapinės priemonės pristatymas cns |
| CA2825810A1 (en) * | 2011-01-28 | 2012-08-02 | Acorda Therapeutics, Inc. | Use of 4-aminopyridine to treat cerebral palsy |
| TN2016000259A1 (en) * | 2016-06-27 | 2017-10-06 | Rekik Raouf | Salbutamol (albuterol) eye protective medicament. |
| WO2018029658A1 (en) * | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| US10485790B1 (en) * | 2018-09-13 | 2019-11-26 | Syneurx International (Taiwan) Corp. | Salts of cycloserine compounds and applications thereof |
| WO2021048431A1 (en) * | 2019-09-12 | 2021-03-18 | Amabiotics | Compounds for treating ataxia |
-
2021
- 2021-05-20 US US17/999,598 patent/US20230201150A1/en active Pending
- 2021-05-20 EP EP21728642.6A patent/EP4153161A1/en active Pending
- 2021-05-20 JP JP2022571228A patent/JP2023526517A/ja active Pending
- 2021-05-20 KR KR1020227045142A patent/KR20230015433A/ko active Pending
- 2021-05-20 WO PCT/IB2021/054399 patent/WO2021234642A1/en not_active Ceased
- 2021-05-20 MX MX2022014466A patent/MX2022014466A/es unknown
- 2021-05-20 CA CA3179105A patent/CA3179105A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230201150A1 (en) | 2023-06-29 |
| WO2021234642A1 (en) | 2021-11-25 |
| JP2023526517A (ja) | 2023-06-21 |
| CA3179105A1 (en) | 2021-11-25 |
| EP4153161A1 (en) | 2023-03-29 |
| KR20230015433A (ko) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202206806B (en) | Benzooxazole derivatives as immunomodulators | |
| ZA202007007B (en) | Mcl-1 inhibitors | |
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| PH12019502379A1 (en) | Pd-1/pd-l1 inhibitors | |
| CL2018000108A1 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| MY201925A (en) | Macrocyclic compounds and uses thereof | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| EP4635568A3 (en) | Compounds, salts thereof and methods for treatment of diseases | |
| AU2018278311A1 (en) | IRE1 small molecule inhibitors | |
| AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
| MX2018005019A (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| MY192703A (en) | Compositions containing tucaresol or its analogs | |
| MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
| MA45780B1 (fr) | Niraparib pour son utilisation dans une méthode de traitement du cancer de la prostate | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| PH12019501722A1 (en) | Compositions and methods for promoting hair growth with mpc1 inhibitors | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2022014466A (es) | Combinacion de acetil leucina y 4-aminopiridina o acetazolamida para tratar la ataxia. | |
| MX393266B (es) | Composiciónpara usarse en terapia de microbiota | |
| PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| MX389692B (es) | Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc. | |
| TR201811308T4 (tr) | Kanser kok hücrelerini azaltan anti-emp2 tedavisi. | |
| CO2019009000A2 (es) | Combinaciones farmacéuticas para tratar cáncer |